Antibe Therapeutics
Antibe Therapeutics Inc. is a Canadian biotechnology company focused on the development of novel, non-addictive therapies for pain and inflammation. The company is headquartered in Toronto, Ontario, and is publicly traded on the Toronto Stock Exchange under the ticker symbol ATE.
History[edit | edit source]
Antibe Therapeutics was founded in 2009 by Dr. John Wallace, a renowned scientist in the field of gastrointestinal health and inflammation. The company was established with the aim of addressing the significant unmet need for safer and more effective pain management solutions.
Technology[edit | edit source]
Antibe Therapeutics utilizes a proprietary hydrogen sulfide-releasing technology to develop its drug candidates. This technology is designed to enhance the safety and efficacy of existing drugs by releasing small amounts of hydrogen sulfide, a naturally occurring gas in the body that has anti-inflammatory and cytoprotective properties.
Pipeline[edit | edit source]
The company's lead drug candidate is ATB-346, a hydrogen sulfide-releasing derivative of naproxen, a widely used nonsteroidal anti-inflammatory drug (NSAID). ATB-346 is being developed for the treatment of osteoarthritis and other chronic pain conditions. Clinical trials have demonstrated that ATB-346 provides effective pain relief with significantly reduced gastrointestinal side effects compared to traditional NSAIDs.
Other drug candidates in Antibe's pipeline include ATB-352, a hydrogen sulfide-releasing derivative of ketoprofen, and ATB-340, a hydrogen sulfide-releasing derivative of aspirin.
Research and Development[edit | edit source]
Antibe Therapeutics is actively engaged in research and development to expand its pipeline of hydrogen sulfide-releasing drugs. The company collaborates with leading academic institutions and research organizations to advance its technology and explore new therapeutic applications.
Leadership[edit | edit source]
The company's leadership team includes experienced professionals from the biotechnology and pharmaceutical industries. Dr. John Wallace serves as the Chief Scientific Officer, and Dan Legault is the Chief Executive Officer.
See also[edit | edit source]
- Biotechnology
- Pharmaceutical industry
- Pain management
- Nonsteroidal anti-inflammatory drug
- Hydrogen sulfide
Related Pages[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
